Why are researchers still fumbling in the quest to cure what is arguably one of the most important diseases confronting ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Donanemab raised the risk of amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients. Many ARIA events ...

But some experts have long warned that side effects of the drug — called donanemab — massively outweigh its benefits. Now, a new study from the company that produces the medication itself ...

But some experts say the side effects of the drug called donanemab may outweigh its benefits. It was given the green light by UK drug regulators, the Medicines and Healthcare Products Regulatory ...

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest this could herald ...

Researchers shed new light on G-quadruplexes, a type of secondary DNA structure that has attracted attention as a potential therapeutic target in cancer.

A new study has been published in Nature Communications, presenting the first comprehensive atlas of allele-specific DNA ...

The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid-targeting Alzheimer’s disease therapy donanemab, delaying its review of ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

Here, Bou-Nader et al., portray the structure, dynamics, and interactions of a complete TAR RNA, and uncovers a convergent viral strategy to evade innate immunity. Qi et al. used cryo-electron ...

The ACS Scholars Program awards renewable scholarships to undergraduate students from historically underrepresented groups in the chemical sciences, majoring in chemistry-related disciplines, and ...